B. Riley Wealth Advisors Inc. Sells 67 Shares of United Therapeutics Co. (NASDAQ:UTHR)

B. Riley Wealth Advisors Inc. lessened its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,000 shares of the biotechnology company’s stock after selling 67 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in United Therapeutics were worth $357,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. ClariVest Asset Management LLC increased its position in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares during the period. Innealta Capital LLC bought a new stake in shares of United Therapeutics in the second quarter worth about $33,000. USA Financial Formulas purchased a new position in United Therapeutics during the 3rd quarter valued at about $33,000. Brooklyn Investment Group bought a new position in United Therapeutics during the 3rd quarter valued at approximately $33,000. Finally, Capital Performance Advisors LLP purchased a new stake in United Therapeutics in the 3rd quarter worth approximately $82,000. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the sale, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,485,785.60. This trade represents a 17.34 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the transaction, the director now owns 5,051 shares of the company’s stock, valued at $1,885,134.22. This represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 145,549 shares of company stock worth $54,547,253. 11.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. LADENBURG THALM/SH SH boosted their target price on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. HC Wainwright boosted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Jefferies Financial Group boosted their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Finally, TD Cowen raised their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Stock Down 0.2 %

United Therapeutics stock opened at $359.58 on Friday. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82. The company has a market capitalization of $16.05 billion, a P/E ratio of 15.79, a PEG ratio of 1.05 and a beta of 0.54. The stock’s 50 day moving average is $371.01 and its 200 day moving average is $344.37.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period in the prior year, the firm posted $5.38 earnings per share. As a group, equities analysts expect that United Therapeutics Co. will post 25.22 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.